$59.70 Million in Sales Expected for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) This Quarter

Share on StockTwits

Wall Street brokerages predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report $59.70 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from $56.90 million to $64.00 million. Vanda Pharmaceuticals reported sales of $53.04 million during the same quarter last year, which would suggest a positive year over year growth rate of 12.6%. The firm is expected to report its next quarterly earnings results on Wednesday, February 12th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $225.87 million for the current fiscal year, with estimates ranging from $223.10 million to $230.00 million. For the next year, analysts expect that the company will post sales of $275.13 million, with estimates ranging from $248.30 million to $327.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the Zacks’ consensus estimate of $0.07 by $1.77. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. The company had revenue of $59.49 million for the quarter, compared to analysts’ expectations of $58.33 million. During the same quarter in the prior year, the company posted $0.13 earnings per share. Vanda Pharmaceuticals’s revenue for the quarter was up 21.1% compared to the same quarter last year.

VNDA has been the topic of a number of recent analyst reports. Stifel Nicolaus reaffirmed a “hold” rating and issued a $17.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, November 7th. Citigroup cut shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 target price on the stock. in a research report on Thursday, November 7th. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 27th. Finally, ValuEngine cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 8th. Two investment analysts have rated the stock with a sell rating and five have issued a hold rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $19.00.

NASDAQ VNDA traded up $0.01 during trading hours on Friday, reaching $16.41. The company had a trading volume of 291,283 shares, compared to its average volume of 540,622. The stock has a 50-day moving average of $16.55 and a 200 day moving average of $14.55. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $31.30. The stock has a market capitalization of $875.31 million, a P/E ratio of 34.19 and a beta of 0.35.

Several institutional investors and hedge funds have recently modified their holdings of VNDA. North Star Investment Management Corp. acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth about $66,000. Meeder Asset Management Inc. lifted its position in shares of Vanda Pharmaceuticals by 1,638.3% during the third quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 4,915 shares in the last quarter. Clarus Wealth Advisors acquired a new stake in Vanda Pharmaceuticals in the third quarter valued at approximately $133,000. Pacer Advisors Inc. acquired a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $138,000. Finally, Zebra Capital Management LLC acquired a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $170,000. 99.29% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: How can investors invest in the S&P/TSX Index?

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.